Related Experiment Videos
D-penicillamine treatment of hyperbilirubinaemia in preterm infants
Insights
Intravenous D-penicillamine treatment effectively reduced hyperbilirubinaemia in preterm infants, particularly those born after 33 weeks gestation. While side effects are possible, they are infrequent with correct usage.
Area of Science:
- Neonatal Medicine
- Pharmacology
Background:
- Hyperbilirubinaemia is a common condition in preterm infants.
- Effective treatment strategies for neonatal jaundice are crucial for preventing complications.
Observation:
- A study involved 41 preterm infants (born before 38 weeks gestation) with hyperbilirubinaemia.
- Intravenous D-penicillamine was administered at 300 mg/kg/day.
Findings:
- D-penicillamine treatment showed favorable results in reducing hyperbilirubinaemia.
- The treatment was particularly effective in infants born after 33 weeks gestation.
- Undesirable side effects were noted but occurred infrequently when indications were appropriate.
Implications:
- Intravenous D-penicillamine may be a viable therapeutic option for hyperbilirubinaemia in specific preterm infant populations.
- Careful patient selection and monitoring are recommended to minimize potential adverse effects.
- Further research could explore optimal dosing and long-term outcomes.
Abstract:
In 41 hyperbilirubinaemic infants born before the 38th gestational week intravenous D-penicillamine treatment was applied in doses of 300 mg/kg body weight/day. As compared to 41 infants of identical gestational age and treated under identical circumstances, penicillamine ensured favourable results, especially in babies born after the 33rd gestational week. Some undesirable side-effects have to be taken into account, but they are infrequent if the indication is correct.